Prognostic Value of Frailty in Aortic Surgery: A Systematic Review and Meta-Analysis Comparing Frailty Assessment Tools.

Ann Vasc SurgJun 29, 2026 (epub)
Clinical ResearchCardiothoracic SurgeryVascular Surgery

Mayara Leite Coutinho, Lucas Monteiro Delgado, Inez Ohashi Torres et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of preoperative frailty in 419,459 patients undergoing aortic surgery. It found that frailty significantly predicts early mortality (OR 2.20) and late mortality (HR 2.18), as well as major complications and nonhome discharge, highlighting the importance of frailty assessment in surgical risk stratification.

Key findings

  • Frailty was associated with higher early mortality (OR 2.20; 95% CI 1.54-3.14).
  • Frail patients had increased risks of major complications (OR 2.52; 95% CI 1.22-5.19).
  • The Modified Frailty Index (mFI)-11 outperformed mFI-5 in predicting outcomes.

Why it matters

Understanding the impact of frailty on surgical outcomes can enhance risk stratification and inform perioperative decision-making, ultimately improving patient care in aortic surgery.

Source

PubMed · PMID 42372863

Published in Ann Vasc Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiothoracic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.